Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
Tofacitinib is an oral Janus kinase (JAK) inhibitor indicated for the treatment of rheumatoid arthritis (RA). The efficacy and safety/tolerability of tofacitinib have been extensively evaluated as monotherapy and combination therapy in multiple, randomised, multicentre studies in patients with RA. T...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326925/ https://www.ncbi.nlm.nih.gov/pubmed/34349573 http://dx.doi.org/10.2147/OARRR.S322086 |